T2DM with SOLIQUA®

T2DM with SOLIQUA^®

Advance your treatment approach for people living with Type 2 Diabetes (PLWD)

Clinical Entry Criteria:

They are on a basal insulin and still not at glycaemic target

HbA1c is between 7 - 9%

BMI is >30, or >27 for the Asian population

A FIXED-RATIO COMBINATION TREATMENT FOR ADULT PATIENTS WITH TYPE 2 DIABETES^1,2

Targets FPG and PPG with 1 x simple daily injection^1,2

Superior HbA_1c reduction vs premix³ Single daily injection associated with greater HbA1c reduction vs basal bolus⁴

1 in 2 patients achieved HbA_1c target < 7 % by week 22⁵

Maintained glycaemic control in an extension study over 52 weeks⁶

Lower glycaemic values at all time points during the day pre- and post-meals after 30 weeks vs insulin glargine 100 U/mL²

SOLIQUA^® Simply effective, every day^3-6

Click here for Soliqua Motivation Letter

FPG: Fasting Plasma Glucose, HbA1c: Hemoglobin A1c, PPG: Postprandial Plasma Glucose, T2DM: Type 2 Diabetes Mellitus

Soliqua^®professional information, August 2024.
Aroda VR, Rosenstock J, Wysham C, et al; the LixiLan-L Trial Investigators. Diabetes Care. 2016;39(11):1972-1980.
Rosenstock J, et al. Diabetes Care. 2021;44(10):2361-2370.
Tabák ÁG, et al. Diabetes Ther. 2020;11:305-318.
Frias J, et al. Diabetes Obes Metab. 2018;20(9):2314-2318. 6. Blonde L,. Diabetes Care. 2021 Mar;44(3):774-780.

For full prescribing information refer to the Professional information approved by the Medicines Regulatory Authority.
SCHEDULING STATUS: S3 PROPRIETARY NAME AND DOSAGE FORM: OPTISULIN^® (solution for injection). COMPOSITION: Each ml of the solution for injection contains 3.64 mg of the active ingredient insulin glargine, corresponding to 100 U human insulin, 2.7 mg of the preservative metacresol and 0.0626 mg of zinc chloride as stabiliser. 10 ml Vial contains 0.02 mg polysorbate 20 as additional stabiliser. REGISTRATION NUMBER: 41/21.1/0363.SCHEDULING STATUS : S3 PROPRIETARY NAME AND DOSAGE FORM: SOLIQUA^® 33/100 solution for injection. SOLIQUA^® 50/100 solution for injection. COMPOSITION: 1 ml of SOLIQUA^® 33/100 pre-filled pen contains 33,0 !g lixisenatide and 3,64 mg insulin glargine (equivalent to 100 units insulin glargine), 2,7 mg of the preservative metacresol, and 0,0626 mg of zinc chloride as stabiliser. 1 ml of SOLIQUA^® 50/100 pre-filled pen contains 500 g lixisenatide and 3,64 mg insulin glargine (equivalent to 100 units insulin glargine), 2,7 mg of the preservative metacresol, and 0,0626 mg of zinc chloride as stabiliser. REGISTRATION NUMBERS: SOLIQUA^® 33/100: 52/32.16/0149 SOLIQUA^® 50/100: 52/32.16/0150. NAME AND BUSINESS ADDRESS OF HOLDER OF THE REGISTRATION CERTIFICATE: sanofi-aventis south africa (pty) ltd., Reg. no. 1996/010381/07. Floor 5, Building 1, Hertford Office Park, 90 Bekker Road, Midrand, 2196. Tel: (011) 256 3700.
For Medical Information Enquiries kindly contact ZA.Medinfo@sanofi.com
Report adverse reactions to za.drugsafety@sanofi.com

MAT-ZA-2500280-1.0-06/2025